Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Sarepta Therapeutics Inc. Shares Skyrocketed

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Sarepta Therapeutics (NASDAQ: SRPT  ) , a clinical-stage RNA-based therapeutics company focused on treating rare and infectious diseases, roared higher by as much as 36% after presenting at the JPMorgan Healthcare Conference and reporting positive results for lead drug, eteplirsen, in a phase 2b study.

So what: According to Sarepta's press release the company's exon-skipping Duchenne muscular dystrophy drug, eteplirsen, "showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test" at the 120-week mark. Based on study statistics, patients in both dosing cohorts experienced a decline of 13.9 meters in walking distance, or less than 5%, from baseline. Study 202, as it's known, also demonstrated a statistically significant treatment benefit of 64.9 meters over the placebo. Even the placebo group, which was switched to eteplirsen from week 25 through 120, demonstrated walk-test improvement and have seen only a decline of 9.5 meters in the week 36 through week 120 time frame.

Now what: Yet again we have data that seems to demonstrate that eteplirsen is effective in treating Duchenne muscular dystrophy. The main hang-ups continue to be what the FDA will accept as a primary indicator of success -- because clearly it didn't like the idea that increased dystrophin production equaled success -- and how critical the FDA will be of eteplirsen given the miserable phase 3 results for GlaxoSmithKline (NYSE: GSK  ) and Prosensa's (NASDAQ: RNA  ) drisapersen, which delivered no demonstrable clinical benefit in a larger study. The data from its midstage study looks intriguing, for certain, but I'm still sticking to the sidelines until we see how eteplirsen fares in a much larger patient pool.

Sarepta may be skyrocketing higher, but this top stock may leave it in the dust when all is said and done!
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2798229, ~/Articles/ArticleHandler.aspx, 8/31/2015 7:57:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 4:00 PM
SRPT $35.70 Down -0.99 -2.70%
Sarepta Therapeuti… CAPS Rating: ***
GSK $40.93 Down -0.32 -0.78%
GlaxoSmithKline CAPS Rating: ****
RNA $0.00 Down +0.00 +0.00%
Prosensa Holding B… CAPS Rating: **